Skip to content

Change in Inventories at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$14M-108%
Gilead Sciences logo
Gilead SciencesGILD
$52M-76.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$4.99M+2,798%
Incyte logo
IncyteINCY
$12.23M-57.2%
Biogen logo
BiogenBIIB
-$116.2M-87.4%
Danaher logo
DanaherDHR
$132M-20.5%

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s change in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s change in inventories?
Iovance Biotherapeutics, Inc. (IOVA) reported change in inventories of $4.93M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s change in inventories changed year-over-year?
Iovance Biotherapeutics, Inc.'s change in inventories decreased by 64.4% year-over-year, from $13.83M to $4.93M.
What does change in inventories mean?
Increase or decrease in inventory levels, directly affecting operating cash flow and working capital.